Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication September 15, 2021
- Revision received January 4, 2022
- Published online September 1, 2022.
Article Versions
- previous version (January 6, 2022 - 13:04).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Ebrahim S. Delpassand1,2,
- Izabela Tworowska2,
- Rouzbeh Esfandiari1,
- Julien Torgue3,
- Jason Hurt3,
- Afshin Shafie1 and
- Rodolfo Núñez1
- 1Excel Diagnostics and Nuclear Oncology Center, Houston, Texas;
- 2RadioMedix, Inc., Houston, Texas; and
- 3Orano Med, Plano, Texas
- For correspondence or reprints, contact Rodolfo Núñez (rnunez{at}exceldiagnostics.com).
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Preclinical Investigation of [212Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model
- Reimagining Biologically Adapted Somatostatin Receptor-Targeted Radionuclide Therapy: Perspectives Based on Personal Experience and Observations on Recent Trials
- Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- 225Ac-MACROPATATE: A Novel {alpha}-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
- The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors